dalteparin has been researched along with hydrogen carbonate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apsner, R; Buchmayer, H; Hörl, WH; Lang, T; Speiser, W; Sunder-Plassmann, G; Unver, B | 1 |
| Fueyo-Rodriguez, O; Moreno-Sanchez, F; Palomar-Lever, A; Valente-Acosta, B | 1 |
1 trial(s) available for dalteparin and hydrogen carbonate
| Article | Year |
|---|---|
Simplified citrate anticoagulation for high-flux hemodialysis.
Topics: Adult; Aged; Analysis of Variance; Anticoagulants; Bicarbonates; Calcium; Chlorides; Citrates; Cross-Over Studies; Dalteparin; Female; Fibrin Fibrinogen Degradation Products; Humans; Magnesium; Male; Middle Aged; Peptide Fragments; Phosphates; Platelet Factor 4; Potassium; Prothrombin; Renal Dialysis; Sodium | 2001 |
1 other study(ies) available for dalteparin and hydrogen carbonate
| Article | Year |
|---|---|
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Azithromycin; Betacoronavirus; Bicarbonates; Ceftriaxone; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Enoxaparin; Enzyme Inhibitors; Fluid Therapy; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Respiration, Artificial; Rhabdomyolysis; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |